Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development

Bispecifics for I&I: Bypassing combination complexity

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting CD28 inside tumor cells for TNBC

BioCentury | Dec 16, 2024
Distillery Therapeutics

CAR Tregs targeting OX40L for GvHD

BioCentury | Dec 10, 2024
Deals

Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar

Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | Aug 1, 2024
Distillery Therapeutics

COL11A1-targeted CAR T cells for pediatric cancers

BioCentury | Aug 1, 2024
Distillery Therapeutics

TYRP1-targeted CAR T cells for immunotherapy-resistant melanoma

BioCentury | Jul 31, 2024
Discovery & Translation

Science Spotlight: CAR tyrosine kinases, disrupting SWI/SNF for lung cancer, and more

BioCentury’s roundup of translational innovations
BioCentury | Jun 13, 2024
Discovery & Translation

Science Spotlight: Lyell’s scaffold for reenergizing CAR T cells; plus Cirrus, Denali and more

BioCentury’s roundup of translational innovations
BioCentury | May 31, 2024
Distillery Therapeutics

Armored, iPSC-derived CAR macrophages for pancreatic cancer

Items per page:
1 - 10 of 237